DAX23.999 -0,5%ESt505.424 -0,6%Top 10 Crypto15,33 +3,3%Dow42.021 +0,4%Nas19.020 +0,8%Bitcoin98.896 +2,2%Euro1,1269 -0,5%Öl64,23 -0,5%Gold3.298 -0,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 RENK RENK73 NVIDIA 918422 D-Wave Quantum A3DSV9 Siemens Energy ENER6Y BYD A0M4W9 Tesla A1CX3T HENSOLDT HAG000 freenet A0Z2ZZ Deutsche Bank 514000 Bayer BAY001 Deutsche Telekom 555750 Infineon 623100 Lufthansa 823212 Allianz 840400
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt unterhalb der 24.000er-Marke -- Umsatz von Snowflake knackt die Milliarde -- Bitcoin mit neuem Rekord -- Beiersdorf, Metaplanet, Strategy, Innoscripta, Rheinmetall im Fokus
Top News
Webinar: Investieren im Zollschock - Chancen, Risiken, Strategien Webinar: Investieren im Zollschock - Chancen, Risiken, Strategien
Salzgitter und Papenburg setzen Partnerschaft fort - Salzgitter-Aktie verliert Salzgitter und Papenburg setzen Partnerschaft fort - Salzgitter-Aktie verliert
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Viking Therapeutics Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
24,60 EUR +0,15 EUR +0,61 %
FSE
27,72 USD +0,48 USD +1,76 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.2,71 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA12GD6

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS92686J1060

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolVKTX

Viking Therapeutics Aktien News

DatumMeistgelesen
BenzingaSpotlight on Viking Therapeutics: Analyzing the Surge in Options Activity
BenzingaHere's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
MotleyFoolViking Therapeutics Stock Is Up by 154% Since January -- Can It Double Again in the Second Half of the Year?
MotleyFool3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
ZacksViking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
BenzingaViking Therapeutics Unusual Options Activity For June 25
PR NewswireViking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association
ZacksWhy Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
MotleyFoolViking Therapeutics Is Great. Here's Why You Shouldn't Buy It
ZacksViking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors
ZacksWall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
BenzingaViking Therapeutics Unusual Options Activity For June 12
MotleyFoolBetter Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
ZacksViking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors
MotleyFoolIs Viking Therapeutics Stock a Buy on the Dip?
BenzingaWhat's Going On With Viking Therapeutics Stock On Tuesday?
PR NewswireViking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
ZacksHere's Why Viking Therapeutics, Inc. (VKTX) Gained But Lagged the Market Today
BenzingaHere's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
PR NewswireViking Therapeutics to Participate at Upcoming Investor Conferences
ZacksWall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
MotleyFoolIf You'd Invested $100 in Viking Therapeutics Stock 2 Years Ago, Here's How Much You'd Have Today
MotleyFoolWhere Will Viking Therapeutics Be in 5 Years?
MotleyFoolIs It Too Late to Buy Viking Therapeutics Stock?
MotleyFoolIs Viking Therapeutics Stock a Buy?
PR NewswireViking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireViking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
PR NewswireViking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
PR NewswireViking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
PR NewswireViking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
PR NewswireViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024
PR NewswireViking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023
PR NewswireViking Therapeutics to Participate at Upcoming Investor Conferences
PR NewswireViking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
PR NewswireViking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
PR NewswireViking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023
PR NewswireViking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
PR NewswireViking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
PR NewswireViking Therapeutics to Participate at Upcoming Investor Conferences
PR NewswireViking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
Wer­bung

Viking Therapeutics News

Viking Therapeutics News: auf dieser Seite finden Sie alle Viking Therapeutics News und Nachrichten zur Viking Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Viking Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Viking Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.